Larimar TherapeuticsSTU:ZA71 34 Current Ratio is 4.29 as of Mar. 2026, which is 55% below its 10-year median of 9.63. GuruFocus rates STU:ZA71 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Larimar Therapeutics ranks better than 52.84% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Larimar Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 4.29.
Larimar Therapeutics has a current ratio of 4.29. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Larimar Therapeutics's Current Ratio or its related term are showing as below:
STU:ZA71'
s Current Ratio Range Over the Past 10 Years
Min: 0.81 Med: 9.63 Max: 20.82
Current: 4.29
During the past 7 years, Larimar Therapeutics's highest Current Ratio was 20.82. The lowest was 0.81. And the median was 9.63.
STU:ZA71's Current Ratio is ranked better than 52.84% of 1410
companies
in the Biotechnology industry
Industry Median: 3.9
vs STU:ZA71: 4.29
Larimar Therapeutics (STU:ZA71) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Larimar Therapeutics Current Ratio Related Terms
Larimar Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Larimar Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZA71 vs XFOR, CMPX, PROK: Current Ratio Comparison
For the Biotechnology subindustry, Larimar Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Larimar Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Larimar Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Larimar Therapeutics (STU:ZA71) has a Current Ratio of 4.29 as of Mar. 2026. This is 55% below median its historical median of 9.63. Over the past decade, Larimar Therapeutics' Current Ratio has ranged from 0.81 to 20.82. According to the industry distribution chart, Larimar Therapeutics ranks #665 out of 1410 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Larimar Therapeutics' Current Ratio too high?
Larimar Therapeutics' current Current Ratio of 4.29 is 55% below median its 10-year median of 9.63. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 20.82. The Biotechnology industry median Current Ratio is 3.90. Larimar Therapeutics' value of 4.29 is 10% above this industry median. Based on the distribution chart, Larimar Therapeutics ranks #665 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' Current Ratio compare to XFOR and CMPX?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #665 out of 1410 companies for Current Ratio. This puts Larimar Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.90. Larimar Therapeutics' value of 4.29 is 10% above this benchmark. Historically, Larimar Therapeutics' own Current Ratio has ranged from 0.81 to 20.82 over the past decade. While the company's 10-year median is 9.63 vs. the industry median of 3.90, Larimar Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Larimar Therapeutics's current Current Ratio of 4.29 is 10% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Larimar Therapeutics's current Current Ratio is 4.29, which is 55% below median its own 10-year median of 9.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (STU:ZA71) has a current Current Ratio of 4.29. The current Current Ratio is 4.29, which is 55% below median its 10-year median of 9.63 and 10% above the Biotechnology industry median of 3.90. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Larimar Therapeutics (STU:ZA71), the current Current Ratio is 4.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score
Get the complete analysis for STU:ZA71
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZA71 has been successfully added to your 
